The Benefits of Molnupiravir Treatment in Healthcare Facilities Patients with COVID-19.
Shih-Lung ChengPing-Huai WangCheng-Yu ChangHsu-Hui WangChung-Jen WangKuan-Ming ChiuPublished in: Drug design, development and therapy (2023)
Initial treatment with MOL has the treatment benefits and is well tolerated for patients with COVID-19 in healthcare facilities. Older age, old CVA, DM, and chronic respiratory diseases were independent risk factors for hospitalization and mortality. The results demonstrate there are important clinical benefits of MOL beyond the reduction in hospitalization or death for these patients with more comorbidities in Taiwan.